{"classes":[{"categories":[{"measurements":[{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG000","spread":"NA","value":"0.2090"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG002","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Avelumab Cycle 1/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"39","value":"20.45"},{"groupId":"OG001","spread":"40","value":"32.34"},{"groupId":"OG002","spread":"63","value":"22.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"Avelumab Cycle 1/Day15-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"136","value":"16.35"},{"groupId":"OG001","spread":"98","value":"31.44"},{"groupId":"OG002","spread":"237","value":"15.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"Avelumab Cycle 2/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23","value":"15.50"},{"groupId":"OG001","spread":"80","value":"57.13"},{"groupId":"OG002","spread":"37","value":"36.04"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"Avelumab Cycle 4/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24","value":"26.38"},{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG001","spread":"NA","value":"77.20"},{"groupId":"OG002","spread":"15","value":"33.23"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Avelumab Cycle 6/Day1-0 Hour"},{"categories":[{"measurements":[{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG001","spread":"NA","value":"46.90"},{"groupId":"OG002","spread":"4","value":"27.09"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"}],"units":"Participants"}],"title":"Avelumab Cycle 10/Day1-0 Hour"},{"categories":[{"measurements":[{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG000","spread":"NA","value":"NA"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"There were \\>2 observations, and no observation was equal or above LLoQ. Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG002","spread":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"PD 0360324 Cycle 1/Day1-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20","value":"126.2"},{"groupId":"OG001","spread":"94","value":"390.9"},{"groupId":"OG002","spread":"101","value":"583.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"title":"PD 0360324 Cycle 1/Day15-0 Hour"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"46","value":"137.7"},{"groupId":"OG001","spread":"110","value":"360.4"},{"groupId":"OG002","spread":"105","value":"2987"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"PD 0360324 Cycle 2/Day1-0 Hour"},{"categories":[{"measurements":[{"comment":"There were \\<=2 participants, and no observation was equal or above LLoQ . Therefore, both Geometric Mean and Geometric Coefficient of Variation could not be calculated.","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"62","value":"447.2"},{"groupId":"OG002","spread":"190","value":"1397"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"title":"PD 0360324 Cycle 4/Day1-0 Hour"},{"categories":[{"measurements":[{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG000","spread":"NA","value":"134.0"},{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG001","spread":"NA","value":"654.0"},{"groupId":"OG002","spread":"128","value":"312.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"}],"units":"Participants"}],"title":"PD 0360324 Cycle 6/Day1-0 Hour"},{"categories":[{"measurements":[{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG001","spread":"NA","value":"115.0"},{"comment":"Only 1 observation was equal or above LLoQ. Only Geometric Mean was reported, and Geometric Coefficient of Variation could not be calculated.","groupId":"OG002","spread":"NA","value":"169.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"title":"PD 0360324 Cycle 10/Day1-0 Hour"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"6"}],"units":"Participants"}],"description":"Ctrough is steady-state pre-dose concentration.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"During Phase 1b participants received PD 0360324 50 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks. Phase 2 was not planned.","id":"OG000","title":"Combination C Phase 1b: PD 0360324 50 mg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 100 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG001","title":"Combination C Phase 1b: PD 0360324 100 mg + Avelumab"},{"description":"During Phase 1b participants received PD 0360324 150 mg IV Q2W with 10 mg/kg of avelumab administered IV Q2W for 2 cycles, where each cycle was of 4 weeks.","id":"OG002","title":"Combination C Phase 1b: PD 0360324 150 mg + Avelumab"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis set included all participants who had received at least one dose of study drug and who had at least one of the PK concentrations of interest for Avelumab, Utomilumab, PD 0360324, PF-04518600. Here, \"Number of participants analyzed'' signifies number of participants evaluable for this outcome measure, where \"Number Analyzed\" signifies number of participants evaluable for specified time points.","reportingStatus":"POSTED","timeFrame":"Pre-dose on Days 1 and 15 of Cycle 1 (non-dosing); Day 1 of Cycles 2, 4, 6 and Cycle 10","title":"Pre-Dose Observed Plasma Concentration (Ctrough) of Avelumab and PD 0360324 in Combination C","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}